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Abstract
Background: Human immunodeficiency virus (HIV) infected patients are at increased risk for the development of
pulmonary arterial hypertension (PAH). Recent reports have demonstrated that HIV associated viral proteins induce
reactive oxygen species (ROS) with resultant endothelial cell dysfunction and related vascular injury. In this study,
we explored the impact of HIV protein induced oxidative stress on production of hypoxia inducible factor (HIF)-1a
and platelet-derived growth factor (PDGF), critical mediators implicated in the pathogenesis of HIV-PAH.
Methods: The lungs from 4-5 months old HIV-1 transgenic (Tg) rats were assessed for the presence of pulmonary
vascular remodeling and HIF-1a/PDGF-BB expression in comparison with wild type controls. Human primary
pulmonary arterial endothelial cells (HPAEC) were treated with HIV-associated proteins in the presence or absence
of pretreatment with antioxidants, for 24 hrs followed by estimation of ROS levels and western blot analysis of
HIF-1a or PDGF-BB.
Results: HIV-Tg rats, a model with marked viral protein induced vascular oxidative stress in the absence of active
HIV-1 replication demonstrated significant medial thickening of pulmonary vessels and increased right ventricular
mass compared to wild-type controls, with increased expression of HIF-1a and PDGF-BB in HIV-Tg rats. The up-
regulation of both HIF-1a and PDGF-B chain mRNA in each HIV-Tg rat was directly correlated with an increase in
right ventricular/left ventricular+septum ratio. Supporting our in-vivo findings, HPAECs treated with HIV-proteins: Tat
and gp120, demonstrated increased ROS and parallel increase of PDGF-BB expression with the maximum induction
observed on treatment with R5 type gp-120CM. Pre-treatment of endothelial cells with antioxidants or transfection
of cells with HIF-1a small interfering RNA resulted in abrogation of gp-120CM mediated induction of PDGF-BB,
therefore, confirming that ROS generation and activation of HIF-1a plays critical role in gp120 mediated up-
regulation of PDGF-BB.
Conclusion: In summary, these findings indicate that viral protein induced oxidative stress results in HIF-1a
dependent up-regulation of PDGF-BB and suggests the possible involvement of this pathway in the development
of HIV-PAH.
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The advent of antiretroviral therapy (ART) has clearly
led to improved survival among HIV-1 infected indivi-
duals, yet this advancement has resulted in the unex-
pected consequence of virus-associated noninfectious
complications such as HIV-related pulmonary arterial
hypertension (HIV-PAH) [1,2]. Despite adherence with
ART, development of HIV-PAH serves as an indepen-
dent predictor of death in patients with HIV-infection
[3]. A precise characterization of the pathogenesis of
HIV-PAH has so far proven elusive. As there is little
evidence for direct viral infection within the pulmonary
vascular bed [4-7], popular hypothesis is that secretary
HIV-1 viral proteins in circulation are capable of indu-
cing vascular oxidative stress and direct endothelial cell
dysfunction and smooth muscle cell proliferation critical
to the development of HIV-related arteriopathy [8,9].
Further, evidence is accumulating which suggests that
the HIV-1 infection of monocyte/macrophages and lym-
phocytes stimulates increased production of pro-inflam-
matory markers and/or growth factors. implicated in the
pathogenesis of HIV-PAH such as platelet derived
growth factor (PDGF)-BB [10-16]. These soluble media-
tors can then initiate endothelial injury followed by
smooth muscle cell proliferation and migration [2,17,18].
Previous studies provide evidence for the possible
involvement of PDGF in the pathogenesis of pulmonary
vascular remodeling in animal models [19,20] and in
lung biopsies from patients with PPH or with HIV-PAH
[12]. Furthermore, a non-specific inhibitor of PDGF sig-
naling, imatinib, has demonstrated the ability to dimin-
ish vascular remodeling in animal studies and to
mitigate clinical decline in human PAH trials [21-24].
Our previous work demonstrates an over-expression of
PDGF in-vitro in HIV-infected macrophages [25] and
in-vivo in Simian HIV-infected macaques [16]. Our
recent work supports an HIV-protein mediated up-regu-
lation of PDGF-BB in un-infectable vascular cell types
such as human primary pulmonary arterial endothelial
and smooth muscle cells [26]. However, the mechanism
(s) by which HIV infection or viral protein(s) binding
induces PDGF expression and the role of this potent
mitogen in the setting of HIV-associated pulmonary
arteriopathy has not been well characterized. HIV asso-
ciated viral proteins including Tat and gp-120 have
demonstrated the ability to trigger the generation of
reactive oxygen species (ROS) [27,28]. As oxidative
stress stabilizes hypoxia inducible factor (HIF)-1a,a
transcription factor critical for regulation of important
proliferative and vaso-active mediators [29-31], we
hypothesize that viral protein generated reactive oxygen
species (ROS) induce HIF-1a accumulation, with a
resultant enhanced transcription of PDGF-B chain.
Thus, given the need for clarification of the mechan-
isms responsible for HIV-related pulmonary vascular
remodeling, we, in the present study, first utilized the
non-infectious NL4-3Δgag/pol HIV-1 transgenic (HIV-
Tg) rat model [32,33] to explore the direct role of viral
proteins in the development of pulmonary vascular
remodeling. This HIV-Tg rat model [34], develops many
clinical multisystem manifestations similar to those
found in AIDS patients and most importantly, has ear-
lier been demonstrated to be under significant oxidative
stress. Furthermore, given that the pulmonary artery
endothelial dysfunction plays a key role in the initiation
and progression of PAH [35-37], utilizing the primary
pulmonary endothelial cell-culture system we next deli-
neated the importance of oxidative stress and HIF-1a
activation in viral protein mediated up-regulation of
PDGF-BB.
Methods
HIV-1 transgenic and wild type rats
HIV-1 transgenic (Tg) Sprague Dawley (SD) and SD
wild type (WT) rats were purchased from Harlan (India-
napolis, Indiana). Young 4-5 months old Tg rats (n =6 )
a n da g em a t c h e dS Dw i l dt y p er a t s( n =6 )w e r eu s e d
for analysis. The HIV-1 Tg rat contains a gag-pol
deleted NL4-3 provirus and expresses HIV viral RNA
and proteins in various tissues including lymphocytes
and monocytes. The animals were euthanized with inha-
lation of 2.5-3% isofluorane gas, followed by transcardial
saline perfusion. Following euthanasia, one half of the
lung was post-fixed for histological examination, while
the other half was snap frozen for RNA analysis. The
animal care at the Kansas University Medical Center
was in strict accordance with the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory
Animals.
Right Ventricular Mass Evaluation
Hearts were removed from the euthanized animals.
After the removal of atria, the wall of the right ventricle
(RV) was separated from the left ventricle (LV) and sep-
tum (LV+S) according to the established method [38].
Wet weights of both RV & LV+S were quantified, nor-
malized to the total body weight and used to calculate
the RV/LV+S ratio.
Histology and immuno-histochemical analysis of
pulmonary arteries
Excised lungs were immersed in 4% paraformaldehyde
overnight followed by 70% ethanol and then used for
paraffin embedding. Paraffin sections of 5 μm thickness
were used for Hematoxylin & Eosin (H&E) or Verhoeff
von Gieson (VVG) staining. The digital scans of whole
Mermis et al. Respiratory Research 2011, 12:103
http://respiratory-research.com/content/12/1/103
Page 2 of 14section from each animal were generated with a Scan-
Scope scanner and then visualized and analyzed using
Aperio image view software. VVG-stained sections from
each animal were evaluated for medial wall thickness of
pulmonary arteries (50-250 μm diameter) in blinded
manner. Wall thickness and outer diameter of approxi-
mately 25 muscularized arteries were measured in each
section at two perpendicular points and then averaged.
The percentage medial wall thickness was then calcu-
lated as described before [39]. Immunohistochemistry
staining of paraffin-embedded lung sections was per-
formed as previously described [16] with primary anti-
bodies including a-SMA, factor VIII, from Dako
Corporation (Carpentaria, CA, USA), HIF-1a,f r o m
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and
PDGF-BB, from Abcam, Inc. (Cambridge, MA).
Cell culture and treatments
Human primary pulmonary microvascular endothelial
cells (HPMVEC) were purchased from ScienCell research
laboratories (Carlsbad, CA) and grown in endothelial cell
basal media containing 2% fetal bovine serum (FBS),
1 μg/ml hydrocortisone, 10 ng/ml human epidermal
growth factor, 3 ng/ml basic fibroblast growth factor, 10
μg/ml heparin, and gentamycin/amphotericin. Cells were
treated with viral proteins: Tat 1-72 (1 μM, University of
Kentucky), gp-120CM or gp-120LAV (100 ng/ml, Protein
Sciences Corporation, Meriden, CT) for 24 hrs or 1 hr
followed by western blot analysis and ROS quantification,
respectively. Tat or gp120 stock solution was heat-inacti-
vated by boiling for 30 min. For treatment with CCR5
neutralizing antibody or IgG isotype control (10 μg/ml,
R&D systems) or; with antioxidant cocktail (0.2 mM
ascorbate, 0.5 mM glutathione, and 3.5 μM a-toco-
pherol), cells were pre-treated with inhibitors for 30 min
followed by treatment with gp-120 CM.
Quantification of cellular oxidative stress using
dichlorofluorescein (DCF) assay
Pulmonary endothelial cells were treated with 5-(and
-6)-carboxy-2’,7 ’-dichlorodihydroflourescein diacetate
(DCFH-DA) (Molecular Probes, Inc.) for 30 min fol-
lowed by treatment with viral protein(s) for 1 hr. In the
presence of H2O2,D C F Hi so x i d i z e dt oaf l u o r e s c e n t
DCF within the cytoplasm which was read by fluores-
cent plate reader at an excitation of 485 nm with an
emission of 530 nm [40].
Transfection of pulmonary endothelial cells with small
interfering (si) RNA
The silencer select pre-designed and validated siRNA
duplexes targeting HIF-1a w e r eo b t a i n e df r o mA p p l i e d
Biosystems (Carlsbad, CA). Cells were also transfected
with silencer select negative control siRNA for compari-
son. HPMVECs were transfected with 10 nM siRNA
using Hiperfect transfection reagent (Qiagen, Valencia,
CA) as instructed by the manufacturer. The transfected
cells were then treated with or without cocaine and/or
Tat for 24 hrs followed by protein extraction for western
blot analysis.
Real-Time RT-PCR analysis
We used Real-Time RT-PCR to analyze RNA extracted
from frozen lungs of HIV-1 Tg rats and WT controls
obtained after non-fixative perfusion. Quantitative analy-
sis of HIF-1a, PDGF and ET-1 mRNA in Tg and WT
rats was done using primers from SA Biosciences (Fre-
derick, MD) by Real-Time RT-PCR using the SYBR
Green detection method. Total RNA was isolated from
frozen lung tissues by lysis in Trizol and was then con-
verted into first strand cDNA to be used for real-time
PCR. Detection was performed with an ABI Prism 7700
sequence detector. The average Ct value of the house-
keeping gene, HPRT, was subtracted from that of target
gene to give changes in Ct (dCt). The fold-change in
gene expression (differences in dCt, or ddCt) was then
determined as log2 relative units.
Western Blot Analysis
Frozen rat lung tissues or endothelial cells were lysed
in lysing buffer (Sigma, St. Louis, MO) containing pro-
tease inhibitors. Protein estimation in these samples
was measured using the micro-BCA method protein
assay kit (Pierce Chemical Co., Rockford, IL). Western
blot analyses were performed using primary antibodies
against HIF-1a (Santa Cruz), PDGF-BB (Santa Cruz),
and b-actin (Sigma). The secondary antibodies used
were horseradish peroxidase-conjugated anti-mouse or
anti-rabbit (1:5000, Pierce Chemical Co) and detection
was performed using the enhanced chemiluminescence
system (Pierce Chemical Co.). The NIH imageJ soft-
ware was used for densitometric analysis of
immunoblots.
Statistical Analysis
Statistical analysis was performed using two-way analy-
sis of variance with a post-hoc Student t- test or non-
parametric Wilcoxon Rank-Sum test as appropriate.
To test for association of RV/LV+septum ratio with
other mediators, the non-parametric Spearman’sr a n k -
sum correlation coefficient was used and coefficient of
determination (R
2) was calculated. Exact two-sided p-
values were calculated for all the analysis, using SAS
9.1 software (SAS Institute, Inc., Cary, NC, USA). A
type I error rate of 5% was used for determining statis-
tical significance.
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Pulmonary vascular remodeling in HIV-Tg rats
Reports suggesting respiratory difficulty in HIV-Tg rats
[34] led us to utilize this model in looking for evidence
of pulmonary arteriopathy associated with HIV-related
proteins. As clinical manifestations of AIDS in HIV-Tg
rats begins as early as 5 months [34], we compared 4-5
months old Tg with age-matched WT-control rats
(n = 6 in each group). Analysis of both, H&E and VVG
staining, of paraffin embedded lung sections from 5
months old HIV-Tg rats demonstrated moderate to
severe vascular remodeling. Representative images of
H&E and VVG staining from each group are shown in
Figure 1A. There was a significant increase in the thick-
ness of the medial wall of muscular arteries in HIV-Tg
rats (Figure 1b, c, e, f) compared to normal vessels in
wild-type control (Figure 1a, d). Further, the presence
of a smooth muscle layer was observed in many of the
normally non-muscular distal arteries of HIV-Tg rats.
The VVG-stained sections from both the groups
revealed a well defined internal elastic lamina (black
stain) in WT-control rats whereas elastic lamina was
found to be disrupted in HIV-Tg rats (Figure 1). As
shown in Figure 2, percentage of medial wall thickness
of pulmonary arteries with outer diameter ranging
between 50-200 μm was observed to be significantly
high in HIV-Tg rats as compared to WT controls
(p < 0.001).
Characterization of pulmonary vascular lesions
in HIV-Tg rats
In order to characterize the cellular composition of pul-
monary vascular lesions in HIV-Tg rats; the lung sec-
tions were stained for a-SMA and Factor VIII. As
shown in the representative lung sections from each
group in Figure 3, we confirmed the presence of vascu-
lar remodeling with medial wall thickness in HIV-Tg
rats while normal blood vessels were observed in WT
control rats. Marked increase in the medial wall thick-
ness of muscular arteries was observed due to increased
proliferation of smooth muscle cells (SMC) in the HIV-
Tg group (Figure 3b) compared to WT controls (Figure
3a). Endothelial monolayer was generally damaged with
signs of increased expression of factor 8 (or vWF) in
both thickened and non-muscular vessels (Figure 3d).
Right ventricular hypertrophy (RVH) in HIV-Tg rats
The HIV-Tg rats exhibited an increase in the ratio of
wet weight of the right ventricle (RV) to the sum of the
wet weights of the left ventricle and interventricular sep-
tum (LV+S), compared to that found in the control
group (Figure 4). This increase in the RV/LV+S ratio
suggests a disproportionate growth of the right ventricle
compared to the left, thereby indicating early RV
hypertrophy in these HIV-Tg rats.
Increased expression of HIF-1a and PDGF-BB in HIV-Tg
rats
Having determined, through observation of right ventri-
cular changes, the degree of pulmonary arteriopathy in
HIV-Tg rats, we next compared the level of HIF-1a
expression in the lungs of these rats to that found in
controls. Although RNA analysis of lung extracts sug-
gested an insignificant increase in the expression of
HIF-1a (p = 0.078) (Figure 5A), western blot analysis
demonstrated significant (p < 0.05) increase in HIF-1a
protein, thus confirming the increase in expression of
HIF-1a in HIV-Tg rats as compared to WT controls
(Figure 5B). This increase in the expression of HIF-1a
was further confirmed by immunohistochemical analysis
on the lung sections from HIV-Tg and WT controls. As
shown in Figure 5C, the lung parenchyma, along with
endothelial cells lining the vessels demonstrating medial
thickness, had strong expression of HIF-1a in the lung
sections from HIV-Tg rats. Enhanced expression was
also observed in mononuclear cells around the thick-
ened vessels. Smooth muscle cells in these arteries, how-
ever, did not demonstrate a significant increase in HIF-
1a compared to those from controls.
We next evaluated the expression of pro-proliferative
factor, PDGF-BB that is suggestive to be regulated in a
HIF-dependent manner [29-31]. As shown in Figure 6A,
real-time RT-PCR analysis of total mRNA extracted
from lung homogenates suggested an increase in the
expression of PDGF-B chain mRNA in HIV-Tg rats
compared to the control rats with normal vasculature.
Interestingly, this increased expression of PDGF-B chain
in the HIV-Tg group was associated positively with the
increase in expression of HIF-1a ( p=0 . 0 0 2 ,R=0 . 9 7 )
(Figure 6B). Furthermore, immunohistochemical analysis
suggested enhanced expression of PDGF-BB in endothe-
lial cells and in mononuclear infiltrated cells around
thickened vessels (Figure 6C) from HIV-Tg rats similar
to HIF-1a staining (Figure 5C). Additionally, the
increased levels of HIF-1a (p = 0.009, R = 0.94) and
PDGF-B chain (p = 0.036, R = 0.78) strongly correlated
linearly with the increased RV/LV+ septum ratio in
HIV-Tg rats (Figure 6D). No notable trends were found
within the wild-type group.
Increased expression of PDGF-BB in HIV-protein(s) treated
pulmonary microvascular endothelial cells
Since we observed increased expression of HIF-1a and
P D G F - B Bi nt h el u n g sf r o mH I V - T gr a t si n c l u d i n g
endothelial cells lining the pulmonary arterial vessels, we
next sought to delineate if HIF-dependent mechanism is
Mermis et al. Respiratory Research 2011, 12:103
http://respiratory-research.com/content/12/1/103
Page 4 of 14Figure 1 Histological evidence of pulmonary vascular remodeling in HIV-Tg rats. Representative images of H& E (a, b, c) and VVG (d, e, f)
stained sections from HIV-Tg (b, c, e, f) and WT control (a, d) rats. H&E photomicrographs were captured at 10× (a, b) and at 20× (c)
magnification whereas VVG images were captured at 4× (d, e) and at 20× (f) original magnification (scale bar: 100 μm). Each representative
image is from different animal.
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PDGF-BB in the pulmonary endothelium. Two major
HIV-proteins: Tat and gp-120 are known to be actively
secreted by infected cells and has been detected in the
serum of HIV-infected patients [41-43]. Furthermore,
given that both Tat and gp-120 were found to express in
the lung homogenates of HIV-Tg rats (data not shown),
we first treated HPMVECs with these viral proteins over
ap e r i o do f2 4h r sa n da s s e s s e df o rt h ee x p r e s s i o no f
PDGF-BB by western blot analysis. As shown in Figure 7,
treatments with Tat, gp-120LAV (from X4-type virus) or
gp-120CM (from R5-type virus) resulted in significant
increase of PDGF-BB protein expression compared to
untreated control. However, when cells were subjected to
treatment with the same concentration of heat inacti-
vated Tat or gp-120, no induction in the PDGF-BB
expression was observed. Additionally, the maximum
increase that was observed on treatment with R5-type
gp-120CM was also significantly more when compared
with the PDGF-BB induction obtained on Tat or X4-type
gp-120LAV treatment.
Reactive oxygen species are involved in HIV-protein
mediated PDGF-BB induction
Since both Tat and gp-120 [27,28,44] are known to
induce oxidative stress, we next evaluated the levels of
cytoplasmic ROS in Tat or gp-120 treated HPMVECs
by DCF assay. Our findings demonstrated that the
treatment of cells with Tat, gp-120LAV or gp-120CM
results in significant increase in the production of ROS
when compared to controls (Figure 8A). Similar to the
PDGF-BB expression the maximum oxidative burst
was observed on treatment with R5 type gp-120CM.
Based on these findings we next focused on elucidating
the mechanism(s) involved in the gp-120CM mediated
up-regulation of PDGF-BB in pulmonary endothelial
cells. We first investigated if chemokine receptor
CCR5 is specifically involved in gp-120CM mediated
generation of ROS by use of CCR5 neutralizing
Figure 2 Increase in medial wall thickness of pulmonary
arteries in HIV-Tg rats compared with WT-rats. VVG-stained
sections from each animal were evaluated for medial wall thickness
of pulmonary arteries with diameter size ranging from 50 μm-250
μm. P < = 0.001, HIV-Tg rats vs. WT controls.
Figure 4 Right ventricular hypertrophy in HIV-Tg rats (n =6 )
compared with age-matched WT rats (n =6 ) . The ratio of the
wet weight of RV wall and of the LV wall with septum of heart (RV/
LV+septum) was measured. P = 0.06, HIV-Tg rats vs. WT controls.
Figure 3 Presence of medial wall thickness in the pulmonary
arteries of HIV-Tg rats. Immuno-histochemistry of paraffin
embedded lung sections with anti- a smooth muscle actin (brown)
(a-b) and factor VIII (brown) (c-d) indicated abnormal vascular
lesions with significant medial wall thickening in the lung sections
from HIV-Tg rats (b, d) compared with WT-controls (a, c).
Representative images were captured at 10× original magnification
(scale bar: 100 μm).
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HPMVECs with CCR5 antibody for 30 min, prevented
the ROS production on gp-120 CM treatment whereas
the pretreatment with isotype matched control anti-
body control had no affect. Furthermore, to examine if
this enhanced levels of ROS are involved in PDGF-BB
increase associated with gp-120CM treatment of pul-
monary endothelial cells, cells were pretreated with
antioxidant cocktail for 30 min. followed by 24 h treat-
ment with gp-120CM. As shown in Figure 8C, western
blot analysis of the total cell extract demonstrated the
ability of antioxidants to prevent the gp-120 CM
mediated increase in the PDGF-BB expression. Taken
together these data suggest the role of oxidative burst
in R5-type gp-120 mediated up-regulation of PDGF-BB
in pulmonary endothelial cells.
ROS dependent stimulation of HIF-1a is necessary for
HIV-protein mediated PDGF-BB induction
It is well known that most of the pathological effects of
ROS in various oxidative stress associated disorders are
mediated by activation and stabilization of HIF-1a [45].
Figure 5 Increased expression of HIF-1a in HIV-Tg rats compared to wild type controls. A) Real-Time RT-PCR analysis of total mRNA and
B) western blot analysis of total protein, extracted from lungs of HIV-Tg rats and age matched wild-type SD rats. Histogram below western blot
image represents the average densitometric ratio of 135 kDa, HIF-1a to b-actin in wild-type and HIV-Tg rats. Statistical significance was
calculated using a two-tail, independent, t-test. (* p < = 0.05) C) Immuno-histochemistry of paraffin embedded lung sections with anti-HIF-1a.
Representative photomicrographs of immunostaining from wild-type and HIV-Tg group are shown. Original magnification: 60×.
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tion of HIF-1a on gp-120CM treatment is important for
increased expression of PDGF-BB in gp-120 treated
HPMVECs. We first examined whether gp-120CM
treatment of HPMVECs could result in increased levels
of HIF-1a protein. As shown in Figure 9A, western blot
analysis of gp-120CM treated cellular extracts demon-
strated increased levels of HIF-1a as compared to
Figure 6 Increased expression of PDGF-B chain in HIV-Tg rats compared to wild type controls. A) Real-Time RT-PCR analysis of total
mRNA in the lungs of HIV-Tg rats and age matched wild-type SD rats. B) Correlation of PDGF-B chain mRNA with the expression of HIF-1a in
HIV-Tg rats. C) Immuno-histochemistry for PDGF-BB on the paraffin embedded lung sections from HIV-Tg and WT rats. Original magnification:
60×. D) Correlation of RV/LV+S ratio with the expression of HIF-1a and PDGF-BB in HIV-Tg rats. Correlation was calculated using the non-
parametric Spearman’s rank correlation coefficient.
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mediated induction of HIF-1a expression was inhibited
on pre-treatment of HPMVECs with an antioxidant
cocktail (Figure 9A), thus confirming the ROS mediated
augmentation of HIF-1a expression on R5 gp-120 treat-
ment of endothelial cells.
Next to determine the involvement of HIF-1a in gp-
120 mediated regulation of PDGF-BB expression, we
used HIF-1a specific siRNA knock down experiments.
First we optimized that the transfection of HPMVECs
with 10nM HIF-1a siRNA was efficient in decreasing
around 80% of gp-120CM induced HIF-1a expression
when compared to cells transfected with non-specific
siRNA control (Figure 9B). Furthermore, the HIF-1a
siRNA transfected cells showed significant decrease in
the expression of PDGF-BB in the presence of gp-120CM
when compared with untransfected or non-specfic
siRNA transfected gp-120CM treated cells (Figure 9C)
thus underscoring the role of HIF-1a activation in the
gp-120CM mediated PDGF-BB expression in pulmonary
endothelial cells.
Discussion
In this study, we offer histological and physiologic evi-
dence of pulmonary vascular remodeling with significant
thickening of medial layer of the arteries, elevated RV
mass in the non-infectious rat model of HIV-1. Pulmon-
ary arteriopathy exhibited by the HIV-Tg rats was mani-
fested primarily by smooth muscle proliferation within
the medial wall, endothelial disruption with little indica-
tion of endothelial cell proliferation but absence of clas-
sic plexiform lesions. Although RV hypertrophy in the
HIV-Tg rats is suggestive of concomitant right heart
pressure overload, the presence of pulmonary arteriopa-
thy alone does not necessarily predict pulmonary hyper-
tension. Furthermore, in humans only a fraction of
individuals with HIV develop PAH, suggesting that the
etiology of HIV-PAH is multi-factorial and complex
where multiple insults such as HIV infection, drugs of
abuse, and genetic predilection may be necessary to
induce clinical disease. Therefore, one could hypothesize
that the viral protein(s) provides the first ‘hit’ and sec-
ond ‘hit’ such as administration of stimulants may lead
to more severe pathology in these HIV-Tg rats.
Inflammation is considered to play an important role
in HIV- associated pulmonary vascular remodeling with
accumulation of macrophages and T lymphocytes found
in the vicinity of pulmonary vessels of pulmonary hyper-
tension patients [46,47]. Consistent with these findings
we also observed infiltration of mononuclear cells near
or around the thickened vessels with mild interstitial
pneumonitis as described before in this model [34].
HIV-1 infection is known to stimulate monocyte/macro-
phages and lymphocytes to secrete elevated levels of
cytokines, growth factors and viral proteins such as Nef,
Tat and gp-120, [10-16] that can then initiate endothe-
lial injury, SMC proliferation and migration, leading to
the development of HIV-PAH [8-10,18,26,48]. It is plau-
sible that the medial wall thickening, an important
determinant of pulmonary vascular resistance, discov-
ered in HIV-Tg rat model is the result of integrated
effects of various HIV proteins and the related inflam-
matory mediators including PDGF-BB.
Examination of the HIV-1 Tg rat lungs revealed
increased staining of PDGF-BB in macrophages around
hypertrophied vessels and in endothelial cells. Earlier
studies suggest induction of PDGF-BB by endothelial
c e l l s[ 4 9 ]b u tn o tb yS M C s[ 5 0 ]i nr e s p o n s et oh y p o x i a .
Furthermore, the vasculature and lungs of this HIV-Tg
rat model has earlier been demonstrated to be under
significant oxidative stress [32,33]. Along the lines, we
observed enhanced expression of HIF-1a, a crucial tran-
scription factor responsible for sensing and responding
to oxidant stress and hypoxic conditions [51], suggest-
ing, in part, the involvement of ROS/HIF-1a pathway in
Figure 7 Increased expression of PDGF-BB in pulmonary
endothelial cells on treatment with HIV-proteins. Representative
western blot showing PDGF-BB expression in cellular extracts from
Tat (25 ng/ml), gp-120LAV (100 ng/ml), gp-120CM (100 ng/ml), heat-
inactivated (HI) Tat or HI-gp-120 treated human pulmonary
microvascular endothelial cells. The blots were re-probed with
human b-actin antibodies. Histogram represents the average
densitometric ratio of PDGF-BB to b-actin of three independent
experiments. Statistical significance was calculated using a two-tail,
independent t-test. (** p ≤ 0.01 vs. control, #p ≤ 0.05 vs. Tat or gp-
120 treatment).
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large program of genes critical to the development of
pulmonary arterial hypertension [29,31,52,53]. Interest-
ingly, the expression of HIF-1a and PDGF was not only
elevated and positively associated with each other in the
lungs of the HIV-1 Tg rats, but the quantity of each was
directly related, in a linear fashion, to the degree of
increase in the right ventricular hypertrophy (RV/LV
+septum ratio).
While these correlations in the HIV-1 transgenic
model are consistent with our hypothesis, our in-vitro
work in pulmonary endothelial cells validates that viral
protein mediated oxidative stress/HIF-1a pathway
results in induction of PDGF-BB. The injury to the
endothelium, an initiating event in PAH [54] is known
to be associated with the induction of oxidative stress
[44]. HIV-associated proteins, Tat and gp-120, as con-
firmed by our findings and others, demonstrate the abil-
ity to invoke oxidative stress mediated endothelial
dysfunction [27,28,44,55]. In addition, results demon-
strating enhanced levels of HIF-1a in viral protein trea-
ted pulmonary endothelial cells, are in concert with the
Figure 8 Involvement of oxidative stress in gp-120 mediated PDGF-BB induction in pulmonary endothelial cells. A) Enhanced oxidative
stress in pulmonary endothelial cells on Tat and gp120 treatment. Human pulmonary microvascular endothelial cells (HPMVECs) were incubated
with carboxy-H2-DCF-DA followed by Tat (25 ng/ml) or gp-120 (100 ng/ml) treatment for 60 min, and assessed for oxidative stress (Mean ± SD.,
**P ≤ 0.01, ***P < 0.001 vs. control). B) Effect of CCR5 neutralizing antibody on gp-120CM (100 ng/ml) mediated oxidative stress in HPMVECs.
Cells were pretreated with CCR5 antibody (10 μg/ml) or equal amount of IgG isotype control for 30 min, followed by DCF assay (Mean ± SD.,
***P < 0.001 treatment versus control; #P < 0.05 vs. gp120CM treatment). C) Gp-120CM mediated PDGF-BB expression in the presence of
antioxidant cocktail. HPMVECs were pretreated with antioxidant cocktail for 30 min followed by incubation with gp-120CM (100 ng/ml) for 24
hours. Cells were then used for protein extraction followed by sequential immunobloting with antibodies specifically directed to the PDGF-BB
and b-actin. Representative western blot images (upper panel) are shown with histograms (lower panel) showing the average densitometric
analysis of the PDGF-BB band normalized to corresponding b-actin band from three independent experiments (*** P < = 0.001 versus control;
###P < = 0.001 versus gp120CM treatment).
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Page 10 of 14Figure 9 Oxidative stress dependent HIF-1a expression is involved in gp-120CM mediated PDGF-BB induction. A) Western blot analysis
of HIF-1a expression in human pulmonary microvascular endothelial cells (HPMVECs) pretreated with or without antioxidant cocktail for 30 min
followed by incubation with gp-120CM (100 ng/ml) for 24 hours. B) Evaluation of HIF-1a knockdown by western blot analysis of whole cell
lysates from HPMVECs transfected with siRNA specific to HIF-1a (10nM) or with negative control siRNA in presence of gp120CM treatment. (C)
Knock down of HIF-1a resulted in inhibition of gp120CM-mediated induction of PDGF-BB expression in HPMVECs. Blots are representative of
three independent experiments with histogram (lower panel) showing the average densitometric analysis normalized to b-actin. All values are
mean ± SD. *P < = 0.01,**P < = 0.001 treatment versus control; #P < = 0.01, ##P < = 0.001 treatment versus gp120CM treated untransfected
cells.
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Page 11 of 14previous findings supporting the activation and accumu-
lation of HIF-1a by HIV-1 through the production of
ROS [56]. PDGF-BB, known to be involved in hypoxia-
induced vascular remodeling, [30,57,58]) has been sug-
gested to be up-regulated in a HIF-dependent manner,
but the mechanism by which HIF-1a and PDGF levels
are elevated during vascular remodeling associated with
PAH, are still not completely understood. A putative
HIF-response element on PDGF-gene has been identi-
fied [59] but the studies demonstrating the direct invol-
vement of HIF-1a in the regulation of PDGF expression
are lacking. Here, we provide evidence validating the
significance of HIF-1a in the pathogenesis of HIV-asso-
ciated vascular dysfunction, and report the novel finding
that its response to viral protein generated oxidative
stress is to augment PDGF expression in the pulmonary
endothelium. To our knowledge, this is the first report
validating that HIV-1 viral proteins through the activa-
tion of HIF-1a induce PDGF expression.
The HIV-1 virus is unable to actively infect endothelial
cells due to the absence of necessary CD4 receptors. How-
ever, viral proteins have been demonstrated to act on
endothelial cells through direct binding to their CCR5
(R5) or CXCR4 (X4) co-receptors [60]. This is corrobo-
rated with our findings showing mitigation of gp-120 CM
response to increase PDGF-BB expression in the presence
of CCR5 neutralizing antibody. Maximum PDGF-BB
expression and ROS production was seen on treatment
with R5-type gp-120 that is expected to be secreted in
abundance by infiltrated HIV-infected CCR5+ T cells [61]
and macrophages seen around the pulmonary vascular
lesions associated with PAH [62]. In addition, studies on
co-receptor usage of HIV have shown that virus utilizing
CCR5 as a co-receptor is the predominant type of virus
found in HIV-infected individuals [63]. Furthermore,
R5gp120 has been reported earlier to induce the expres-
sion of cell-cycle and cell proliferation related genes more
strongly than X4 gp-120 in peripheral blood mononuclear
cells [64] and this differential potency of gp-120 effect may
be present in pulmonary endothelial cells as well.
Conclusion
In summary, we demonstrate that the influence of HIV-
1 proteins alone, without viral infection, is associated
with pulmonary arteriopathy including accumulation of
HIF-1a a n dP D G Fa so b s e r v e di nt h eH I V - 1T gr a t s .
Furthermore, our in-vitro findings confirm that HIV-1
viral protein mediated generation of oxidative stress and
resultant activation of HIF-1a leads to subsequent
induction of PDGF expression in pulmonary endothelial
cells. Consistent with a possible role of PDGF in the
development of idiopathic PAH, the correlation of this
mediator with RVH, does suggest this pathway may be
one of the many insults involved in the development of
HIV-related pulmonary arteriopathy and potentially
HIV-PAH.
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